Connexion
Connexion
Ou se connecter avec
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Inscription
Ou se connecter avec
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

CELLECTIS S.A.

(ALCLS)
  Rapport
Temps réel Euronext Paris  -  09:20 28/11/2022
2.298 EUR   -0.69%
16/11Les actions européennes stagnent dans des échanges agités mercredi alors que les tensions géopolitiques pèsent sur elles
MT
11/11Séance de gala à Wall Street
ZB
11/11En direct des marchés : Teleperformance, Airbus, Richemont, Cellnex, EDF, Alstom, Holcim, Akwel...
ZB
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFonds 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur CELLECTIS S.A.
24/11Cellectis S A : Document AMF CP. 2022E873261
21/11Cellectis S A : Document AMF CP. 2022E872622
18/11Cellectis S A : Document AMF CP. 2022E872470
16/11European Equities Flat in Choppy Trade Wednesday as Geopolitical Tensions Weigh
11/11Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling ..
11/11Cellectis Presents Pre-Clinical Data on TALEN-edited Smart CAR T-cells Overcoming Key C..
10/11European ADRs Surge Higher as Global Markets React to US Inflation Data
10/11Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key ..
10/11Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key ..
10/11Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling ..
09/11European ADRs Move Lower in Wednesday Trading
08/11European ADRs Move Higher in Tuesday Trading, Adding to Monday's Gains
04/11Transcript : Cellectis S.A., Q3 2022 Earnings Call, Nov 04, 2022
04/11Bolsa de Madrid: Y China emerge...
03/11Cellectis S A : PRELIMINARY NOTE - Form 6-K
03/11Cellectis S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended Sep..
03/11Cellectis Provides Business Update and Reports Financial Results for Third Quarter and ..
03/11Cellectis Provides Business Update and Reports Financial Results for Third Quarter and ..
03/11Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at..
03/11Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at..
03/11Cellectis to Showcase Clinical Data from Ameli-01 and Preclinical Data from Ucartcs1 At..
31/10European ADRs Move Lower in Monday Trading
27/10Cellectis to Report Third Quarter 2022 Financial Results
27/10Cellectis to Report Third Quarter 2022 Financial Results
26/10European ADRs Move Higher in Wednesday Trading
21/10European ADRs Move Higher in Friday Trading
12/10Cellectis Presents Data on Two TALEN-based Gene Therapy Preclinical Programs for Patien..
12/10Bolsa de Madrid: El peso de las palabras
11/10Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patie..
11/10Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patie..
11/10Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patie..
11/10Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infil..
10/10European ADRs Move Lower in Monday Trading
07/10European ADRs Move Lower in Friday Trading
06/10Bolsa de Madrid: El mercado recupera parte de su libido
05/10Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Im..
05/10Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Im..
05/10European ADRs Move Sharply Lower in Wednesday Trading
03/10Calyxt, Inc. : Entry into a Material Definitive Agreement, Other Events, Financial Stateme..
29/09European ADRs Move Lower in Thursday Trading
29/09Biopharmaceutical Group Cellectis Hires Chief Medical Officer
28/09Cellectis Promotes Mark Frattini to Chief Medical Officer
28/09Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer
28/09Cellectis Appoints Mark Frattini as Chief Medical Officer
27/09Cellectis S A : Document AMF CP. 2022E863159
23/09European ADRs Fall in Friday Trading
23/09Allogene Stocks Fall as Servier Abandons Anti-CD19 Partnership
22/09Cellectis S.A. and Les Laboratoires Servier Sas and Institut De Recherches Internationa..
22/09Calyxt, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
21/09European ADRs Move Lower in Wednesday Trading
20/09European ADRs Move Lower in Tuesday Trading
19/09Zentalis Pharmaceuticals Hires Carrie Brownstein as Chief Medical Officer
08/09European ADRs Move Slightly Higher in Thursday Trading
07/09European ADRs Move Lower in Wednesday Trading
07/09Transcript : Cellectis S.A. Presents at Citi's 17th Annual BioPharma Conferen..
06/09European ADRs Move Higher in Tuesday Trading
05/09Cellectis S A : Corporate Presentation - September 2022
02/09European ADRs Climb Sharply Higher in Friday Trading
01/09Cellectis Announces Participation in Four Upcoming Investor Conferences in September
01/09Cellectis S A : Document AMF CP. 2022E858948
31/08European ADRs Fall in Wednesday Trading
26/08European ADRs Move Lower in Friday Trading
25/08Cellectis S A : Document AMF CP. 2022E858188
24/08European ADRs Move Lower in Wednesday Trading
22/08European ADRs Move Lower in Monday Trading
19/08European ADRs Move Lower in Friday Trading
18/08European ADRs Move Lower in Thursday Trading
17/08European ADRs Move Lower in Wednesday Trading
16/08Cellectis S A : Document AMF CP. 2022E857305
15/08European ADRs Move Sharply Lower in Monday Trading
12/08European ADRs Move Slightly Lower in Friday Trading
11/08European ADRs Move Lower in Thursday Trading
10/08Cellectis S A : Document AMF CP. 2022E856958
09/08European ADRs Move Higher in Tuesday Trading
08/08European ADRs Move Higher in Monday Trading
05/08European ADRs Move Lower in Friday Trading
05/08Transcript : Cellectis S.A., Q2 2022 Earnings Call, Aug 05, 2022
04/08Cellectis S A : PRELIMINARY NOTE - Form 6-K
04/08Calyxt : Q2 Earnings Snapshot
04/08Cellectis S A : Provides Business Update and Reports Financial Results for Second Quarter ..
04/08Cellectis S A : Provides Business Update and Reports Financial Results for Second Quarter ..
04/08CALYXT, INC. Management's Discussion and Analysis of Financial Condition and Results o..
04/08Cellectis S.A. Reports Earnings Results for the Second Quarter and Six Months Ended Jun..
04/08Cellectis S.A. Announces Executive Changes
04/08Cellectis Provides Business Update and Reports Financial Results for Second Quarter 202..
04/08European ADRs Move Higher in Thursday Trading
03/08European ADRs Nudge Higher in Wednesday Trading
02/08Cellectis Receives FDA Clearance to Launch Phase 1/2a Lymphoma Trial
02/08Cellectis Gets US FDA Nod To Start Trial For Non-Hodgkin Lymphoma Treatment
01/08Cellectis S A : Receives IND clearance for UCART20x22, its First in-house Manufactured Pro..
01/08Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Produc..
01/08Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Produc..
01/08Cellectis S.A. Announces U.S. Food and Drug Administration Clear Cellectis’ Invest..
01/08European ADRs Move Higher in Monday Trading
28/07Cellectis S A : to Report Second Quarter 2022 Financial Results - Form 6-K
28/07Cellectis to Report Second Quarter 2022 Financial Results
28/07Cellectis to Report Second Quarter 2022 Financial Results
28/07European ADRs Decline in Thursday Trading
27/07European ADRs Move Higher in Wednesday Trading
20/07European ADRs Move Lower in Wednesday Trading